PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32743640-0	2021	Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations.	vandetanib	15-25	tumor protein p53	Homo sapiens	104-108	
32743640-8	2021	Irinotecan and vandetanib are prospective drugs for PAAD patients with KRASG12Dmutation and TP53 mutation.	vandetanib	15-25	tumor protein p53	Homo sapiens	92-96	
20665703-6	2011	ZD6474 inhibited cyclin D1 and cyclin E expression and induced p53 expression when combined with paclitaxel.	vandetanib	0-6	tumor protein p53	Homo sapiens	63-66	
28159923-2	2017	SHH-TP53-mutated as well as MYC-amplified Non-WNT/Non-SHH medulloblastoma show the worst prognosis.Here we present evidence that single application of the multi-kinase inhibitor Vandetanib displays anti-neoplastic efficacy against cell lines derived from high-risk SHH-TP53-mutated and MYC-amplified Non-WNT/Non-SHH medulloblastoma.	vandetanib	178-188	tumor protein p53	Homo sapiens	4-8	
28159923-2	2017	SHH-TP53-mutated as well as MYC-amplified Non-WNT/Non-SHH medulloblastoma show the worst prognosis.Here we present evidence that single application of the multi-kinase inhibitor Vandetanib displays anti-neoplastic efficacy against cell lines derived from high-risk SHH-TP53-mutated and MYC-amplified Non-WNT/Non-SHH medulloblastoma.	vandetanib	178-188	tumor protein p53	Homo sapiens	269-273	
28159923-4	2017	In this context our investigation documents that Vandetanib in combination with the clinically available PI3K inhibitor GDC-0941 leads to enhanced cytotoxicity against MYC-amplified and SHH-TP53-mutated medulloblastoma.	vandetanib	49-59	tumor protein p53	Homo sapiens	190-194	
28159923-7	2017	Of note, the combination of Vandetanib, GDC-0941 and Etoposide results in MYC-amplified and SHH-TP53-mutated cell lines in complete loss of cell viability.	vandetanib	28-38	tumor protein p53	Homo sapiens	96-100	
24138843-8	2013	ZD6474 inhibited cyclin E expression and induced p53 expression when combined with UV-B.	vandetanib	0-6	tumor protein p53	Homo sapiens	49-52